Transgene to start large-scale trials of new AIDS drug
27 Dec 2010
Transgene Biotech has initiated the process of large-scale animal trials - both through transdermal and oral delivery - of its new therapeutic AIDS vaccine candidate TBL-1203 following some successful trials.
Trangene said it has achieved another milestone in the development of AIDS vaccine with its TBL-1203 molecule demonstrating its efficiency in selective killing of gpl20 specific B cells within 48 hours of its administration.
The new vaccine, which is designed and formulated to make administration of the drug more effective and easier, especially for those living in the developing countries, the company said in a release.
The uniqueness of the drug delivery system is significant considering TBL-1202 AIDS drug is protein-based and hence very difficult to deliver other than through injectible routes, the company said.
The company sees bright prospects for the drug considering its potential ability to halt the progress of AIDS and restoring health to those affected by AIDS.
Transgene said it continues to make progress across its oncology pipeline through new gene silencing drugs for metatstatic breast and lever cancers using proprietary delivery system and also its monoclonal antibody-based drugs against multiple myeloma, colon cancer etc.
Transgene said its biogeneric drug development pipeline is also advancing well.
.webp)
